Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Relypsa: An In-depth Analysis of Early Results of the Veltassa Launch (RLYP, Buy, $13.26)

Investment Perspective

Relypsa is about two months into the launch of Veltassa, its first product. There was a time (several years…
Read more…

Effective Treatment of Hyperkalemia Promises to be a Multi-billion Opportunity

Key Points

There are no effective treatment options for long term treatment of hyperkalemia (high potassium levels).
My research suggests that the…
Read more…